Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Peter Lynch Fair Value : $9.93 (As of May. 14, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Clinuvel Pharmaceuticals's PEG is 1. Clinuvel Pharmaceuticals's 5-Year TTM EBITDA Growth Rate is 25. Clinuvel Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.40. Therefore, the Peter Lynch Fair Value for today is $9.93.

As of today (2024-05-14), Clinuvel Pharmaceuticals's share price is $10.00. Clinuvel Pharmaceuticals's Peter Lynch fair value is $9.93. Therefore, Clinuvel Pharmaceuticals's Price to Peter Lynch Fair Value Ratio for today is 1.01.

The historical rank and industry rank for Clinuvel Pharmaceuticals's Peter Lynch Fair Value or its related term are showing as below:

CLVLF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.03 Med: 1.34 Max: 1.47
Current: 1.05

During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Clinuvel Pharmaceuticals was 1.47. The lowest was 1.03. And the median was 1.34.

CLVLF's Price-to-Peter-Lynch-Fair-Value is ranked better than
65.88% of 85 companies
in the Biotechnology industry
Industry Median: 1.56 vs CLVLF: 1.05

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.

Clinuvel Pharmaceuticals Peter Lynch Fair Value Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Peter Lynch Fair Value Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Peter Lynch Fair Value

Get a 7-Day Free Trial

6.62

9.92

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Peter Lynch Fair Value	Get a 7-Day Free Trial															-	6.62	-	9.92	-

Competitive Comparison of Clinuvel Pharmaceuticals's Peter Lynch Fair Value

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value falls into.

Clinuvel Pharmaceuticals Peter Lynch Fair Value Calculation

Clinuvel Pharmaceuticals's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value	=	PEG Ratio	*	5-Year TTM EBITDA Growth Rate^**	*	EPS without NRI (TTM)
	=	1	*	25	*	0.397
	=	9.93

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.40.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

Clinuvel Pharmaceuticals's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value	=	Share Price	/	Peter Lynch Fair Value
	=	10.00	/	9.93
	=	1.01

Clinuvel Pharmaceuticals Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Peter Lynch Fair Value

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.